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Objective: To discuss the expression of long noncoding RNA TUG1 (lncRNA-TUG1)
in gastric carcinoma (GC) and its effects on the transferring and invading capacity of
gastric carcinoma cells.
Methods: Forty cases of carcinoma tissue and para-carcinoma tissue were selected from
GC patients who underwent surgical removal in Zhejiang Provincial Hospital of Chinese
Traditional Medicine and Wenzhou Central Hospital from January, 2013 to December,
2014; the expressing level of lncRNA-TUG1 in GC and para-C tissues was detected by
applying the qRT-PCR technique. The correlation between lncRNA-TUG1 expression
and patients' clinical data was classiﬁed and analyzed. SGC-7901 cells were transfected
using lncRNA-TUG1 speciﬁc siRNA. Changes of the transferring and invading capacity
of siRNA-transfected SGC-7901 cells were scratch-tested and transwell-detected. qRT-
PCR was applied to detect the expression level of microRNA-144 after lncRNA-TUG1
was silenced. Changes of c-Met mRNA and protein expressions was detected by qRT-
PCR and western-blot test.
Results: The expression level of lncRNA-TUG1 in GC tissue was signiﬁcant higher than
that in para-C tissue (P < 0.05) and the high expression level of lncRNA-TUG1 in GC
tissue was signiﬁcantly correlated with tumor lymph nodes metastasis and advance TNM
phasing (P < 0.05). The transferring and invading capacity of SGC-7901 cells was highly
inhibited after being transfected by lncRNA-TUG1 speciﬁc siRNA (P < 0.05). The re-
sults of qRT-PCR and western-blot proved that the expression of microRNA-144 was
signiﬁcantly boosted and the expression level of c-Met mRNA and protein was inhibited
after lncRNA-TUG1 was silenced (P < 0.05).
Conclusions: lncRNA-TUG1 shows an up-regulated expression in GC tissue and that
bears a correlation with clinicopathological features of malignant tumor. lncRNA-TUG1
can promote the transferring and invading capacity of GC by inhibiting the pathway of
microRNA-144/c-Met.rticle under the CC BY-NC-ND license (http://
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Gastric carcinoma is a common malignant tumor of digestive
system [1]. Due to the features of concealed morbidity, rapid
development and easy postoperative recurrence, gastric
carcinoma has become one of the most major public health
problems that jeopardize Chinese people's health [2]. Because
molecular targeting treatment has signiﬁcant application value
in gastrointestinal tumors [3], the study of the molecular
biological characteristics of gastric carcinoma cells is of great
importance in ﬁnding new therapeutic target and improving
the diagnosis and treatment of gastric carcinoma.
lncRNA is a type of non-decoding single stranded RNA
with a length of above 200 nucleotides [4]. More and more
evidence [5] shows that lncRNA, by multiple ways, can
regulate a variety of pathological processes including the
growth and transference of tumor and angiogenesis so as to
facilitate the occurrence and development of malignant
tumors. The abnormal expression of lncRNA and its
biological function is one of the research highlights of
gastric carcinoma molecular pathology in recent years. In a
latest research, it is indicated that lncRNA-TUG1 has signiﬁ-
cant regulatory function in the developing process of cancers
[6], but its clinical signiﬁcance to gastric carcinoma and
biological functions are still unclear. This study, by detecting
the expression of lncRNA-TUG1 and its functions in regu-
lating the transferring and invading processes of SGC-
7901 cells, explores the clinical signiﬁcance and functional
mechanism of lncRNA-TUG1 in the development of gastric
carcinoma so as to provide theoretical basis to the molecular
diagnosis and targeted therapy of gastric carcinoma.2. Materials and methods
2.1. Clinical specimens and primary reagent
Carcinoma tissue and para-carcinoma tissue (>2 cm away
from the tumor) were selected as clinical specimens from forty
gastric carcinoma patients with an average age of 51.2 ± 1.1
years who underwent surgical removal in Zhejiang Provincial
Hospital of Chinese Traditional Medicine and Wenzhou Central
Hospital from January, 2013 to December, 2014. None of the
forty patients had conducted chemoradiotherapy before under-
going surgery. All the specimens were preserved in liquid ni-
trogen. qRT-PCR kit was purchased from Beijing Tiangen
Biotechnology Limited company. Both lncRNA-TUG1 siRNA
and negative control siRNA was purchased from Shanghai Jima
Biotechnology Limited Company. Trizol reagent and lip-
ofectamineTM 2000 was from American Invitrogen company;
miR-144 qRT-PCR primers kits from Guangzhou Ruibo
Biotechnology Limited Company; lncRNA-TUG1 primers
(forward primer 50-TAGCAGTTCCCCAATCCTTG-30; reverse
primer 50-TAGCAGTTCCCCAATCCTTG-30), c-Met primers
(forward primer 50-GTCGGAGTAGAGCGTCGAGA-30;
reverse primer 50-CAGCGCGATCAGGTA GAGC-30) and
b-actin primers (forward primer 50-CTCCATCCTGGCCTCG
CTGT-30; reverse primer 50-GCTGTCACCTTCACCGTTCC
-30) were all synthesized by Shanghai Shenggong Biotechnology
Limited Company; matrigel was from American BD company;
Transwell from American Corning Company; rabbit-anti-human
c-Met polyclonal antibody and mouse-anti-human b-actinmonoclonal antibody from American CST company; fetal calf
serum from Zhengjiang Tianhang Biotechnology Limited
Company; 1×DMEM ﬂuid nutrient medium from American
HyClone Company; human gastric carcinoma cells SGC-7901
from Cell Resource Center, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences; RIPA lysate, BCA
protein quantiﬁcation kit and ECL kit all from Shanghai
Biyuntian Biotechnology Institute.
2.2. RNA extraction and qRT-PCR
The TRIZOL instruction was followed; carcinoma and para-
carcinoma tissues and total RNA of SGC-7901 were extracted.
Detecting with ultraviolet spectrophotometer, only those whose
OD260/OD280 ratio ranged from 1.9 to 2.1 could be classiﬁed
as qualiﬁed sample. 500 ng total RNA was taken as a template
and reverse transcription reaction system was prepared accord-
ing to the RT-PCR kit instruction and Random 6 and Oligo-dT
double-primer methods were adopted to reversely transcribe
lncRNA and mRNA. After the reverse transcription, real-time
PCR system was prepared with 2 uL cDNA and target genes
were ampliﬁed according to real-time PCR speciﬁcations.
Similarly, use miR-144 qRT-PCR kit to amplify miR-144 by
following the same steps.
2.3. Cell culture
SGC-7901 cells were all inoculated in 1×DMEM medium
that contained 10% fetal calf serum and were cultivated in a
37 C incubator that contained 5% CO2 with saturation hu-
midity. After 2–3 stable generations, logarithmic-phased cells
were taken for subsequent tests.
2.4. Cell transfection
SGC-7901 cells were inoculated in a six-well plate. Inoc-
ulum density will be subject to alignment of up to 50% after
the overnight cultivation. According to the Lipofectamine®
2000 speciﬁcation, transfection system was prepared with
serum-free DMEM medium for each well: total volume: 2 mL,
DMEM: 1500 mL, Lipo 2000+DMEM: 5 mL + 250 mL, siR-
NA+DMEM: 100 pmol+250 mL. SGC-7901 cells were trans-
fected with lncRNA-TUG1 siRNA and NC siRNA. After six
hours' transfection, complete medium with 10% fetal calf
serum was used.
2.5. Cell scratch healing test
24h-transfected SGC-7901 cells were taken and cultivated in
six-well plate overnight till fusion reached above 90%. The
original medium was absorbed and removed and then the cells
were washed twice in PBS solution. 100 mL spearhead was used
to make scratch and then remnant cells were washed away by
PBS solution. The cells were cultivated in 1×DMEM medium
with 5% serum for 48 h and the healing state of the scratched
cells was observed under the inverted microscope.
2.6. Transwell
Matrigel was diluted by 1×DMEM medium. The basilar
membrane of Transwell was coated with 100 mL per hole. 48h-
Table 1
Correlation between the expression of lncRNA-TUG1 and GC patients'
clinical pathological characteristics (n = 40).
Item Category Relative expression of
lncRNA-TUG1
P
Age <50 5.279 ± 0.201 0.737
50 5.581 ± 0.132
Hp infected or
not
Infected 5.493 ± 0.111 0.868
Uninfected 5.334 ± 0.207
Tumor diameter <2 cm 5.138 ± 0.097 0.063
2 cm 5.495 ± 0.114
Tumor quantity 1 5.374 ± 0.211 0.068
2 5.537 ± 0.182
Histological
grade
G1~G2 5.289 ± 0.107 0.083
G3 5.513 ± 0.132
Lymphatic
metastasis
N/A 3.043 ± 0.037 0.017*
A 5.588 ± 0.071
TNM phasing N/A 3.117 ± 0.068 0.021*
A 5.883 ± 0.120
Note: *P < 0.05.
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pended in a serum-free medium; the cell density was adjusted
into 1 × 105/mL and then inoculated in the upper well of the
Transwell. 750 mL 10%-serum DMEM medium was added into
each hole of the 24-well plate. After 24 h' culture in the medium,
the supernatant medium was discarded and the remains were
washed twice with PBS. After that, the remains were ﬁxed with
4% paraformaldehyde and stained with crystal violet. The
remnant cells were wiped off from the surface of the upper well
with cotton swab and then the number of cells on the surface of
lower well was counted under microscope.
2.7. Western blot
72h-transfected SGC-7901 cells were collected and cleaved
by RIPA lysate and the total protein concentration was
measured by adopting the BCA method. After separating the
protein by vertical electrophoresis, 1:1000 diluted c-Met and
b-actin primary antibodies were combined with corresponding
target protein; 1:5000 diluted HRP-marked goat anti-rabbit
antibody was combined with primary antibody. The relative
expression of protein was detected by ECL Chem-
iluminescence method.
2.8. Statistical analysis
All data were analyzed by SPSS 21.0 and data were
expressed as mean ± SD. Comparison among groups was con-
ducted by t test or ANOVA test. P < 0.05 showed statistically
signiﬁcant difference.
3. Results
3.1. Expression difference of lncRNA-TUG1 in gastric
carcinoma and para-carcinoma tissue
The expressions of lncRNA-TUG1 in 40 pairs of gastric
carcinoma and para-carcinoma RNA specimens were detected
by qRT-PCR. Results showed that the relative expression of
lncRNA-TUG1 in gastric carcinoma tissue was (5.487 ± 0.301),
while only (2.304 ± 0.027) in the corresponding para-carcinoma
tissue showing signiﬁcant difference between the two specimen
groups (P < 0.001).
3.2. Correlation between the abnormal expression of
lncRNA-TUG1 in gastric carcinoma tissue and patients'
clinical characteristics
In order to ﬁnd out whether the abnormal expression of
lncRNA-TUG1 in gastric carcinoma tissue had effect on pa-
tients' clinical pathological manifestations, a dichotomy was
conducted among clinical pathological characteristics and the
relative expression of lncRNA-TUG1 was counted. It was
discovered through statistical analyses that high expression of
lncRNA-TUG1 in GC tissue had some correlations with tumor
lymph nodes metastasis (>2 cm) and high TNM phasing (III+IV
phase), which implies that lncRNA-TUG1 may have some
biological function in the developing process of gastric carci-
noma (see Table 1).3.3. Effects of silent lncRNA-TUG1 on the transference
and invasion of SGC-7901 cells
With instant transfection technique and Lipofectamine® 2000
as medium, lncRNA-TUG1 speciﬁc siRNA or NC siRNA was
transfected into SGC-7901 cells. qRT-PCR detection proved that
lncRNA-TUG1 speciﬁc siRNA signiﬁcantly decreased the
expression level of lncRNA-TUG1 (1.000 ± 0.000 vs.
0.301 ± 0.012, P < 0.001).
After the expression of lncRNA-TUG1 in SGC-7901 cells
was successfully silenced, scratch healing test was ﬁrst applied
to detect the effects of lncRNA-TUG1's expression change on
the transferring capacity of SGC-7901 cells. Compared with NC
group, the transferring capacity of SGC-7901 cells was greatly
inhibited (20.651 ± 3.817 vs. 75.160 ± 4.332, P = 0.008) after
the knockdown of lncRNA-TUG1. Further detection in Trans-
well revealed that silencing lncRNA-TUG1 can substantially
weaken SGC-7901's invasion (41.223 ± 3.781 vs.
63.574 ± 5.152, P = 0.007).
3.4. Effects of down-regulating lncRNA-TUG1 on the
expression of miR-144/c-Met in SGC-7901 cells
One of lncRNA's functional mechanisms is that it can
combine with various RNA sequences including microRNA
through molecular sponge effect so as to silence its functions. It
was speculated through bioinformatics search that miR-144 may
be one of lncRNA-TUG1's combining targets. In order to verify
this, qRT-PCR detection was carried out after the expression of
lncRNA-TUG1 was silenced in SGC-7901 cells and it was
found that the expression quantity of miR-144's increases
considerably. It was also learned through bioinformatics search
and literature review that tyrosine kinase receptor c-Met may be
one of miR-144's targets. qRT-PCR and western-blot detections
were conducted and it was discovered that c-Met's mRNA and
protein level showed a signiﬁcant decrease indicating it was
probable that lncRNA-TUG1 inhibited the expression of miR-
144 and activated c-Met to promote tumorigenesis (see Table 2).
Table 2
Effects of silencing lncRNA-TUG1 on the expression of miR-144/c-Met
in SGC-7901 cells.
Symbol NC siRNA TUG1 siRNA
miR-144 1.000 ± 0.000 2.133 ± 0.074
C-Met mRNA 1.000 ± 0.000 0.376 ± 0.0248**
C-Met protein 0.871 ± 0.039 0.420 ± 0.026**
**P < 0.001, vs. NC siRNA group.
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Millions of people all over the world suffer from gastric
carcinoma every year. At present, the morbidity rate of GC ranks
high among those of malignant tumors in both China and
Western countries [7]. With the development of molecular
biotechnology, biological targeted therapy has become an
important assistant treatment for GC. Cetuximab [8] and
bevacizumab [9] have been successfully used for treating GC.
Therefore, the search and study of effective molecular
therapeutic targets play an important role in improving the
prognosis of GC patients.
Today increasing evidence shows that multiple kinds of
noncoding RNA, such as (microRNA) [10] and lncRNA [11] have
great effects on cells' physiological and pathological processes.
Besides, the abnormal expression of ncRNA in diseases shows
enormous potential for drug research and development. So far
there have been two type of microRNA: miR-122, miR-34
entering the clinical research stage [12]. lncRNA-TUG1 is a
newly found type of lncRNA that can regulate the growth of
tissues and the development of various benign and malignant
diseases. lncRNA-TUG1 shows a higher expression level in
pancreatic tissue and its expression is regulated by glucose
langerhans. The knockdown of lncRNA-TUG1 in pancreatic b
can facilitate cell apoptosis and suppress insulin secretion [13].
For malignant tumors [14], the abnormal expression of
lncRNA-TUG1 has great value in monitoring clinic treatment
and evaluating prognosis. The research of Tan et al. [15]
indicates that the expression of lncRNA-TUG1 is considerably
up-regulated in bladder carcinoma tissues, which is correlated
with the EMT transformation of tumor cells and postoperative
radiotherapy resistance. The results of survival analysis curve
also verify that lncRNA-TUG1's high expression indicates
relatively short postoperative tumor-free survival time and total
survival time. As a result, it is believed that changes of lncRNA-
TUG1's expression level bear close correlation with the prog-
ress, transference and recrudesce of tumors.
In this study, it is ﬁrst proved in clinical tissue specimens that
lncRNA-TUG1 has a high expression in GC tissue. With
different clinical pathological characteristics as subgroups, ana-
lyses show that lncRNA-TUG1's high expression is closely
related with GC patients' lymphatic metastasis and high TNM
phasing. The results of this study is consistent with those con-
cerning osteosarcoma [16] and glioma [17,18]. In order to explore
the biological functions of lncRNA-TUG1 in GC cells, the
speciﬁcity of siRNA is applied to knocking down the expression
of lncRNA-TUG1 in SGC-7901 cells and scratch healing test
and Transwell detection are carried out to certify that silenced
lncRNA-TUG1 can inhibit the transferring and invading ca-
pacity of cells. Both histology and cytology experiments
demonstrate that lncRNA-TUG1 has certain facilitating effects
in the transferring process of GC cells.The effecting mechanism of lncRNA is quite complicated.
One important mechanism is that it can act as molecular sponge
and combine with microRNA so as to inhibit its silencing effect
on downstream target mRNA [19–21]. Through the search on
bioinformatics websites such as Starbase [22], it is learned that
miR-144 may be one of lncRNA-TUG1's binding molecules
and miR-144 is also certiﬁed to have signiﬁcant anti-GC effects
[23–25]. To sum up, we hypothesize that lncRNA-TUG1's
facilitating effect on the transference and invasion of GC cells
is probably realized by inhibiting the expression and function
of miR-144. In order to verify this hypothesis, we apply
siRNA transfection technique to knock down the expression of
lncRNA-TUG1 in SGC-7901 cells. Through qRT-PCR detec-
tion, it is discovered that silenced lncRNA-TUG1 notably en-
hances the expression of miR-144 in SGC-7901 cells. Further
study shows that after silencing lncRNA-TUG1, the expression
of c-Met, the downstream target of miR-144 in SGC-7901 cells,
which has facilitating effect on the invasion of tumor cells, is
also inhibited. So far we have preliminarily ascertained the
affecting mechanism of lncRNA-TUG1.
In conclusion, lncRNA-TUG1 manifests a tremendous
expressing rise in GC tissue. It is very likely that by inhibiting
miR-144, lncRNA-TUG1 indirectly activates the expression of
c-Met so as to promote the transference and invasion of GC
cells. Thus, lncRNA-TUG1 possesses certain value of research
and development in the biological targeted therapy of GC.
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